Drug intelligence / Profile preview

ephedrine

Development stage
Approved
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Intravenous, Oral, Intranasal
01

Overview

Ephedrine is a sympathomimetic amine and central nervous system stimulant used primarily to treat clinically significant hypotension during anesthesia, bronchial asthma (as a bronchodilator), nasal congestion (as a decongestant), and occasionally for weight loss. It is naturally derived from the Ephedra plant and was first described in Western literature in 1888. Ephedrine acts as both a direct agonist at alpha-1, beta-1, and beta-2 adrenergic receptors and as an indirect sympathomimetic by promoting the release of norepinephrine from sympathetic neurons while inhibiting its reuptake. This dual mechanism results in increased blood pressure (vasoconstriction), cardiac stimulation (increased heart rate and contractility), bronchodilation, and CNS stimulation. Its use has declined for some indications due to the development of more selective adrenergic agonists.

Brand names
AkovazCorphedraEmerphedRezipres
Other names
ephedrine sulfateephedrine hydrochlorideEphedrinum
02

Targets

ADRA1A (α1A)NET (Norepinephrine Transporter)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on ephedrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ephedrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call